Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC

NCT00328653 is registered in ClinicalTrials.gov with Santen SAS as lead sponsor.

NCT NCT00328653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00328653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC
Lead sponsor
Santen SAS
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2006
Completion date
Not reported
Enrollment
118 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

conjunctivitis, vernal